VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
GKOSGlaukos Corporation
$130.68$7.6B
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksGKOSP/E History

GKOS logoGlaukos Corporation (GKOS) P/E Ratio History

Deep Value

Trading at -39.8x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2016–2019

Current P/E (TTM)
-39.8x
-109% vs 5Y avg
5Y Avg P/E
428.2x
Median 451.6x
5Y Percentile
0th
Lower end of range
PEG Ratio
N/A
5-Year P/E Range
-39.8x
Min207.2xMedian451.6xMax776.5x
TTM EPS$-3.26
Price$130.68
Earnings YieldN/A
EPS Growth (1Y)-18.4%
EPS Growth (5Y)N/A

Loading P/E history...

P/E Ratio Analysis

As of June 21, 2026, Glaukos Corporation (GKOS) trades at a price-to-earnings ratio of -39.8x, with a stock price of $130.68 and trailing twelve-month earnings per share of $-3.26.

The current P/E is 109% below its 5-year average of 428.2x. Over the past five years, GKOS's P/E has ranged from a low of 207.2x to a high of 776.5x, placing the current valuation at the 0th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.1x, GKOS trades at a 280% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.

Relative to the broader market, GKOS trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our GKOS DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

GKOS Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
-39.8vs22.1
-280%
Below Sector
vs. S&P 500
-39.8vs24.4
-263%
Below Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on -18% EPS growth (1Y)

GKOS P/E vs Peers

Vision, dental, and ENT devices peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
INSP logoINSPInspire Medical Systems, Inc.
$1B8.7Lowest-+179%Best
EW logoEWEdwards Lifesciences Corporation
$50B47.76.74Best-74%
ALGN logoALGNAlign Technology, Inc.
$13B32.2-+1%
HOLX logoHOLXHologic, Inc.
$17B30.5--25%
LNTH logoLNTHLantheus Holdings, Inc.
$7B30.5--22%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

GKOS Historical P/E Data (2016–2019)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2019 Q4-$54.47$0.26207.2x-52%
FY2017 Q1Mar 31 2017$51.30$0.11451.6x+5%
FY2016 Q4Dec 31 2016$34.30$0.12277.5x-35%
FY2016 Q3Sep 30 2016$37.74$0.05776.5x+81%

Average P/E for displayed period: 428.2x

Export Data
Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

GKOS — Frequently Asked Questions

Quick answers to the most common questions about buying GKOS stock.

What is GKOS's P/E ratio?

Glaukos Corporation (GKOS) trailing twelve-month P/E ratio is -39.8x, based on TTM diluted EPS of $-3.26. The 5-year average P/E is 428.2x and the historical range spans 207.2x to 776.5x.

Is GKOS stock overvalued or undervalued?

GKOS trades at -39.8x P/E, below its 5-year average of 428.2x. At the 0th percentile of its historical range (207.2x–776.5x), the stock is priced at a discount to its own history.

Is GKOS stock expensive?

No, GKOS is not expensive on a historical basis. The current P/E of -39.8x is below the 5-year average of 428.2x and sits at the 0th percentile of its valuation range.

What is GKOS's historical P/E range?

Over the past 5 years, GKOS's P/E ratio has ranged from 207.2x to 776.5x, with a median of 451.6x and an average of 428.2x. The current P/E of -39.8x places the stock at the 0th percentile of this range. Full historical data spans 2016–2019.

How does GKOS's P/E compare to the S&P 500?

GKOS trades at -39.8x P/E versus the S&P 500 median of 24.4x. The 263% discount to the market suggests lower growth expectations or perceived higher risk.

How does GKOS's valuation compare to Healthcare peers?

Glaukos Corporation P/E of -39.8x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is GKOS's PEG ratio?

GKOS PEG ratio is N/A, based on a P/E of -39.8x and EPS growth of -18.4%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.

What is GKOS's earnings yield?

GKOS earnings yield is N/A, the inverse of its -39.8x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

GKOS P/E Ratio History (2016–2019)

Quarterly valuation multiple from closing price and trailing EPS

Current207.2x
Period Avg428.2x
Range207.2x - 776.5x
Change-73%
4 quartersSep 30, 2016 - Dec 31, 2019